Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

Late clinical-stage biopharmaceutical company Vistagen has announced that the European Patent Office (EPO) plans to grant a patent for its PH80 nasal spray, which is designed to treat migraines. The patent claims include treatment administered at the onset of migraine symptoms and treatment of migraines associated with traumatic brain injury. PH80 nasal spray initiates neural impulses in the olf..